198 related articles for article (PubMed ID: 27059733)
1. Galectin-3 induces ovarian cancer cell survival and chemoresistance via TLR4 signaling activation.
Cai G; Ma X; Chen B; Huang Y; Liu S; Yang H; Zou W
Tumour Biol; 2016 Sep; 37(9):11883-11891. PubMed ID: 27059733
[TBL] [Abstract][Full Text] [Related]
2. TLR4 and NFκB signaling is critical for taxol resistance in ovarian carcinoma cells.
Sun NK; Huang SL; Chang TC; Chao CC
J Cell Physiol; 2018 Mar; 233(3):2489-2501. PubMed ID: 28771725
[TBL] [Abstract][Full Text] [Related]
3. Atractylenolide-I sensitizes human ovarian cancer cells to paclitaxel by blocking activation of TLR4/MyD88-dependent pathway.
Huang JM; Zhang GN; Shi Y; Zha X; Zhu Y; Wang MM; Lin Q; Wang W; Lu HY; Ma SQ; Cheng J; Deng BF
Sci Rep; 2014 Jan; 4():3840. PubMed ID: 24452475
[TBL] [Abstract][Full Text] [Related]
4. TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer.
Szajnik M; Szczepanski MJ; Czystowska M; Elishaev E; Mandapathil M; Nowak-Markwitz E; Spaczynski M; Whiteside TL
Oncogene; 2009 Dec; 28(49):4353-63. PubMed ID: 19826413
[TBL] [Abstract][Full Text] [Related]
5. The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer.
Bates M; Spillane CD; Gallagher MF; McCann A; Martin C; Blackshields G; Keegan H; Gubbins L; Brooks R; Brooks D; Selemidis S; O'Toole S; O'Leary JJ
PLoS One; 2020; 15(12):e0243715. PubMed ID: 33370338
[TBL] [Abstract][Full Text] [Related]
6. Compound A attenuates toll-like receptor 4-mediated paclitaxel resistance in breast cancer and melanoma through suppression of IL-8.
Sootichote R; Thuwajit P; Singsuksawat E; Warnnissorn M; Yenchitsomanus PT; Ithimakin S; Chantharasamee J; Thuwajit C
BMC Cancer; 2018 Feb; 18(1):231. PubMed ID: 29486738
[TBL] [Abstract][Full Text] [Related]
7. The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer.
d'Adhemar CJ; Spillane CD; Gallagher MF; Bates M; Costello KM; Barry-O'Crowley J; Haley K; Kernan N; Murphy C; Smyth PC; O'Byrne K; Pennington S; Cooke AA; Ffrench B; Martin CM; O'Donnell D; Hennessy B; Stordal B; Finn S; McCann A; Gleeson N; D'Arcy T; Flood B; O'Neill LA; Sheils O; O'Toole S; O'Leary JJ
PLoS One; 2014; 9(6):e100816. PubMed ID: 24977712
[TBL] [Abstract][Full Text] [Related]
8. Icariside II potentiates paclitaxel-induced apoptosis in human melanoma A375 cells by inhibiting TLR4 signaling pathway.
Wu J; Guan M; Wong PF; Yu H; Dong J; Xu J
Food Chem Toxicol; 2012 Sep; 50(9):3019-24. PubMed ID: 22743248
[TBL] [Abstract][Full Text] [Related]
9. PFKFB3 potentially contributes to paclitaxel resistance in breast cancer cells through TLR4 activation by stimulating lactate production.
Ge X; Cao Z; Gu Y; Wang F; Li J; Han M; Xia W; Yu Z; Lyu P
Cell Mol Biol (Noisy-le-grand); 2016 May; 62(6):119-25. PubMed ID: 27262815
[TBL] [Abstract][Full Text] [Related]
10. Role of the TLR4-androgen receptor axis and genistein in taxol-resistant ovarian cancer cells.
Huang SL; Chang TC; Chao CCK; Sun NK
Biochem Pharmacol; 2020 Jul; 177():113965. PubMed ID: 32278794
[TBL] [Abstract][Full Text] [Related]
11. TLR4/IL-6/IRF1 signaling regulates androgen receptor expression: A potential therapeutic target to overcome taxol resistance in ovarian cancer.
Huang SL; Chang TC; Chao CCK; Sun NK
Biochem Pharmacol; 2021 Apr; 186():114456. PubMed ID: 33556340
[TBL] [Abstract][Full Text] [Related]
12. Role of TLR4 for paclitaxel chemotherapy in human epithelial ovarian cancer cells.
Wang AC; Su QB; Wu FX; Zhang XL; Liu PS
Eur J Clin Invest; 2009 Feb; 39(2):157-64. PubMed ID: 19200169
[TBL] [Abstract][Full Text] [Related]
13. TLR4 is a novel determinant of the response to paclitaxel in breast cancer.
Rajput S; Volk-Draper LD; Ran S
Mol Cancer Ther; 2013 Aug; 12(8):1676-87. PubMed ID: 23720768
[TBL] [Abstract][Full Text] [Related]
14. Sialyltransferase ST3GAL1 promotes cell migration, invasion, and TGF-β1-induced EMT and confers paclitaxel resistance in ovarian cancer.
Wu X; Zhao J; Ruan Y; Sun L; Xu C; Jiang H
Cell Death Dis; 2018 Oct; 9(11):1102. PubMed ID: 30375371
[TBL] [Abstract][Full Text] [Related]
15. Galectin-3 activates TLR4/NF-κB signaling to promote lung adenocarcinoma cell proliferation through activating lncRNA-NEAT1 expression.
Zhou W; Chen X; Hu Q; Chen X; Chen Y; Huang L
BMC Cancer; 2018 May; 18(1):580. PubMed ID: 29788922
[TBL] [Abstract][Full Text] [Related]
16. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
17. MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression.
Chen WT; Yang YJ; Zhang ZD; An Q; Li N; Liu W; Yang B
J Ovarian Res; 2017 Jan; 10(1):1. PubMed ID: 28086946
[TBL] [Abstract][Full Text] [Related]
18. Pectasol-C Modified Citrus Pectin targets Galectin-3-induced STAT3 activation and synergize paclitaxel cytotoxic effect on ovarian cancer spheroids.
Hossein G; Halvaei S; Heidarian Y; Dehghani-Ghobadi Z; Hassani M; Hosseini H; Naderi N; Sheikh Hassani S
Cancer Med; 2019 Aug; 8(9):4315-4329. PubMed ID: 31197964
[TBL] [Abstract][Full Text] [Related]
19. Synergistic effects of PectaSol-C modified citrus pectin an inhibitor of Galectin-3 and paclitaxel on apoptosis of human SKOV-3 ovarian cancer cells.
Hossein G; Keshavarz M; Ahmadi S; Naderi N
Asian Pac J Cancer Prev; 2013; 14(12):7561-8. PubMed ID: 24460334
[TBL] [Abstract][Full Text] [Related]
20. ERp57‑small interfering RNA silencing can enhance the sensitivity of drug‑resistant human ovarian cancer cells to paclitaxel.
Li S; Zhao X; Chang S; Li Y; Guo M; Guan Y
Int J Oncol; 2019 Jan; 54(1):249-260. PubMed ID: 30431082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]